Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
Salmen J, Sohn C, Fehm T, Mohrmann S, Loehberg C, Hein A, Schulz-Wendtland R, Hartkopf A, Brucker S, Wallwiener D, Friese K, Hartmann A, Beckmann M, Janni W, Rom J, Heil J, Neugebauer J, Fasching P, Haeberle L, Huober J, Wöckel A, Rauh C, Schuetz F, Weissenbacher T, Kost B, Stickeler E, Klar M, Orlowska-Volk M, Windfuhr-Blum M, Rack B. Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast Cancer Res Treat 2014; 148:143-51.
25.09.2014Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
25.09.2014Breast Cancer Res Treat 2014; 148:143-51
Salmen Jessica, Sohn Christof, Fehm Tanja, Mohrmann Svjetlana, Loehberg Christian R, Hein Alexander, Schulz-Wendtland Ruediger, Hartkopf Andreas D, Brucker Sara Y, Wallwiener Diethelm, Friese Klaus, Hartmann Arndt, Beckmann Matthias W, Janni Wolfgang, Rom Joachim, Heil Joerg, Neugebauer Julia, Fasching Peter A, Haeberle Lothar, Huober Jens, Wöckel Achim, Rauh Claudia, Schuetz Florian, Weissenbacher Tobias, Kost Bernd, Stickeler Elmar, Klar Maximilian, Orlowska-Volk Marzenna, Windfuhr-Blum Marisa, Rack Brigitte
Pulmonary actinomycosis and Hodgkin's disease: when FDG-PET may be misleading
Weisshaupt C, Hitz F, Albrich W, Omlin A. Pulmonary actinomycosis and Hodgkin's disease: when FDG-PET may be misleading. BMJ Case Rep 2014; 2014
22.09.2014Pulmonary actinomycosis and Hodgkin's disease: when FDG-PET may be misleading
22.09.2014BMJ Case Rep 2014; 2014
Weisshaupt Christian, Hitz Felicitas, Albrich Werner, Omlin Aurelius
Tumor clone dynamics in lethal prostate cancer
Carreira S, Demichelis F, S de Bono J, Tunariu N, Flohr P, Rodrigues D, Omlin A, Pezaro C, Frenel J, Lorente D, Prandi D, Miranda S, Ferraldeschi R, Grist E, Goodall J, Romanel A, Attard G. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 2014; 6:254ra125.
17.09.2014Tumor clone dynamics in lethal prostate cancer
17.09.2014Sci Transl Med 2014; 6:254ra125
Carreira Suzanne, Demichelis Francesca, S de Bono Johann, Tunariu Nina, Flohr Penelope, Rodrigues Daniel Nava, Omlin Aurelius, Pezaro Carmel, Frenel Jean-Sebastien, Lorente David, Prandi Davide, Miranda Susana, Ferraldeschi Roberta, Grist Emily, Goodall Jane, Romanel Alessandro, Attard Gerhardt
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer
Blagden S, Spicer J, Twelves C, Jones K, Prince J, Inatani M, Shiokawa R, Noguchi K, Pope L, Riisnaes R, Swales K, Decordova S, Anthoney A, Pinato D, Zivi A, Stavraka C, Josephs D, Omlin A, Banerji U. First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. Clin Cancer Res 2014; 20:5908-17.
17.09.2014First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer
17.09.2014Clin Cancer Res 2014; 20:5908-17
Blagden Sarah, Spicer James, Twelves Chris, Jones Keith, Prince Jenny, Inatani Michiyasu, Shiokawa Rie, Noguchi Kohei, Pope Lorna, Riisnaes Ruth, Swales Karen, Decordova Shaun, Anthoney Alan, Pinato David J, Zivi Andrea, Stavraka Chara, Josephs Debra, Omlin Aurelius, Banerji Udai
Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe
Fizazi K, Wirth M, Wiegel T, Miller K, McDermott R, James N, Hamdy F, Gschwend J, Gillessen Sommer S, de Wit R, Culine S, Castellano D, Bellmunt J, Ahlgren G, Abrahamsson P, Tombal B. Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. Eur Urol 2014
10.09.2014Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe
10.09.2014Eur Urol 2014
Fizazi Karim, Wirth Manfred, Wiegel Thomas, Miller Kurt, McDermott Raymond, James Nicholas, Hamdy Freddie, Gschwend Juergen E, Gillessen Sommer Silke, de Wit Ronald, Culine Stéphane, Castellano Daniel, Bellmunt Joaquim, Ahlgren Goran, Abrahamsson Per-Anders, Tombal Bertrand
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer
Loibl S, Fasching P, Andre F, Lindner J, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Pfitzner B, Huober J, Heinrichs C, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm D, Sinn P, Khandan F, Eidtmann H, Dohnal K, Denkert C. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014; 32:3212-20.
08.09.2014PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer
08.09.2014J Clin Oncol 2014; 32:3212-20
Loibl Sibylle, Fasching Peter A, Andre Fabrice, Lindner Judith L, Sotiriou Christos, Dykgers August, Guo Sanxing, Gade Stephan, Nekljudova Valentina, Loi Sherene, Untch Michael, Pfitzner Berit, Huober Jens, Heinrichs Clemens, von Minckwitz Gunter, Schneeweiss Andreas, Paepke Stefan, Lehmann Annika, Rezai Mahdi, Zahm Dirk M, Sinn Peter, Khandan Fariba, Eidtmann Holger, Dohnal Karel, Denkert Carsten
Komplementärmedizin in der Onkologie
Schlaeppi M, Templeton A. Komplementärmedizin in der Onkologie - Was der Grundversorger wissen sollte. Swiss Medical Forum 2014; 14:689-693.
08.09.2014Komplementärmedizin in der Onkologie
08.09.2014Swiss Medical Forum 2014; 14:689-693
Schlaeppi Marc, Templeton Arnoud
Spirituelle Begleitung in Leid und Krankheit
Renz M (2014). Spirituelle Begleitung in Leid und Krankheit. Präsentiert bei: UniversitätsSpital Zürich, Klinik für Hämatologie, Zürich
06.09.2014Spirituelle Begleitung in Leid und Krankheit
06.09.2014UniversitätsSpital Zürich, Klinik für Hämatologie
Renz Monika
Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis
Templeton A, Diez-Gonzalez L, Ace O, Vera-Badillo F, Seruga B, Jordán J, Amir E, Pandiella A, Ocana A. Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. Cancer Treat Rev 2014; 40:1048-55.
03.09.2014Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis
03.09.2014Cancer Treat Rev 2014; 40:1048-55
Templeton Arnoud, Diez-Gonzalez Laura, Ace Olga, Vera-Badillo Francisco, Seruga Bostjan, Jordán Joaquín, Amir Eitan, Pandiella Atanasio, Ocana Alberto
Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics
Mukherji D, Omlin A, Pezaro C, Shamseddine A, de Bono J. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. Cancer Metastasis Rev 2014; 33:555-66.
01.09.2014Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics
01.09.2014Cancer Metastasis Rev 2014; 33:555-66
Mukherji Deborah, Omlin Aurelius, Pezaro Carmel, Shamseddine Ali, de Bono Johann
Neurologische Komplikationen bei onkologischen Patienten
Hundsberger T, Roth P, Roelke U. Neurologische Komplikationen bei onkologischen Patienten. Praxis 2014 2014; 103:1009-1016.
25.08.2014Neurologische Komplikationen bei onkologischen Patienten
25.08.2014Praxis 2014 2014; 103:1009-1016
Hundsberger Thomas, Roth Patrick, Roelke Ulrich
[Neurological complications in cancer patients]
Hundsberger T, Roth P, Roelcke U. [Neurological complications in cancer patients]. Praxis (Bern 1994) 2014; 103:1009-16.
20.08.2014[Neurological complications in cancer patients]
20.08.2014Praxis (Bern 1994) 2014; 103:1009-16
Hundsberger Thomas, Roth Patrick, Roelcke Ulrich
Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone
Leibowitz-Amit R, Alimohamed N, Vera-Badillo F, Seah J, Templeton A, Knox J, Tannock I, Sridhar S, Joshua A. Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone. Prostate 2014; 74:1462-4.
11.08.2014Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone
11.08.2014Prostate 2014; 74:1462-4
Leibowitz-Amit Raya, Alimohamed Nimira, Vera-Badillo Francisco E, Seah Jo-An, Templeton Arnoud, Knox Jennifer J, Tannock Ian F, Sridhar Srikala S, Joshua Anthony M
Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment
Vera-Badillo F, Ocana A, Templeton A, Tibau A, Amir E, Tannock I. Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment. J Clin Oncol 2014; 32:3197.
04.08.2014Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment
04.08.2014J Clin Oncol 2014; 32:3197
Vera-Badillo Francisco E, Ocana Alberto, Templeton Arnoud, Tibau Ariadna, Amir Eitan, Tannock Ian F
Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients
Bock C, Rack B, Huober J, Andergassen U, Jeschke U, Doisneau-Sixou S. Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients. Future Oncol 2014; 10:1751-65.
01.08.2014Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients
01.08.2014Future Oncol 2014; 10:1751-65
Bock Carolin, Rack Brigitte, Huober Jens, Andergassen Ulrich, Jeschke Udo, Doisneau-Sixou Sophie
Massive human rivaroxaban overdose.
Lehmann T, Hofer K, Baumann M, Hasler K, Ceschi A, Kupferschmidt H, Rohde G, Korte W. Massive human rivaroxaban overdose. Thromb Haemost 2014; 112:834-6.
24.07.2014Massive human rivaroxaban overdose.
24.07.2014Thromb Haemost 2014; 112:834-6
Lehmann Thomas, Hofer Katharina E, Baumann Michael, Hasler Karin, Ceschi Alessandro, Kupferschmidt Hugo, Rohde Gabriele, Korte Wolfgang
Harmlose blaue Flecken? Gerinnungsstörung trotz normaler INR
Greuter L, Schöb M, Lehmann T, Diethelm M. Harmlose blaue Flecken? Gerinnungsstörung trotz normaler INR. Praxis (Bern 1994) 2014; 103:899-902.
23.07.2014Harmlose blaue Flecken? Gerinnungsstörung trotz normaler INR
23.07.2014Praxis (Bern 1994) 2014; 103:899-902
Greuter Ladina, Schöb Manuela, Lehmann Thomas, Diethelm Markus
Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole
Leibowitz-Amit R, Sridhar S, Tannock I, Knox J, Alimohamed N, Vera-Badillo F, Templeton A, Atenafu E, Seah J, Joshua A. Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. Eur J Cancer 2014; 50:2399-407.
16.07.2014Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole
16.07.2014Eur J Cancer 2014; 50:2399-407
Leibowitz-Amit Raya, Sridhar Srikala S, Tannock Ian F, Knox Jennifer J, Alimohamed Nimira, Vera-Badillo Francisco E, Templeton Arnoud, Atenafu Eshetu G, Seah Jo-An, Joshua Anthony M
Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes
de Bruin G, Groll M, van der Marel G, van der Stelt M, Driessen C, Kisselev A, Kim K, Al-Ayed K, van Rooden E, Xin B, Huber E, Overkleeft H. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes. J Med Chem 2014; 57:6197-209.
15.07.2014Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes
15.07.2014J Med Chem 2014; 57:6197-209
de Bruin Gerjan, Groll Michael, van der Marel Gijsbert A, van der Stelt Mario, Driessen Christoph, Kisselev Alexei F, Kim Kyung-Bo, Al-Ayed Karol, van Rooden Eva J, Xin Bo-Tao, Huber Eva M, Overkleeft Herman S
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio
Templeton A, Tannock I, de Bono J, Attard G, Vera-Badillo F, Leibowitz-Amit R, McNamara M, Omlin A, Pezaro C, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer 2014; 120:3346-52.
03.07.2014Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio
03.07.2014Cancer 2014; 120:3346-52
Templeton Arnoud, Tannock Ian F, de Bono Johann S, Attard Gerhardt, Vera-Badillo Francisco E, Leibowitz-Amit Raya, McNamara Mairead G, Omlin Aurelius, Pezaro Carmel, Amir Eitan